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Background: To assess the trends of risk classification and primary therapy in Japanese patients who were
diagnosed with prostate cancer between 2004-2006 and 2007-2009.
Methods: A total of 4752 patients who were newly diagnosed with prostate cancer at Nara Medical University and
its 23 affiliated hospitals between 2004 and 2009 were enrolled. The differences in risk classification and primary
therapy were compared in patients who were newly diagnosed between 2004-2006 (prior period) and 2007-2009
(latter period).
Results: The proportion of patients with a high or greater risk significantly decreased in the latter period compared
to the prior period (p < 0.001). The proportion of primary androgen deprivation therapy (PADT) was 50% in the
prior period, and 40% in the latter period. On the other hand, the proportion of radiation therapy was 14% in the
prior period, but 24% in the latter period. The proportion of radical prostatectomy was the same in the two periods
(30%). The primary therapy was significantly different between the two periods (p < 0.001).
Conclusions: Higher risk patients significantly decreased in the latter period compared to the prior period. The use
of PADT also significantly decreased in the latter period. However, there were still higher risk patients in Japan, and
the use of PADT was still common in patients with localized prostate cancer or locally advanced prostate cancer in
Japan.
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There is a distinctive trend in Japan that a large proportion
of patients who are diagnosed with prostate cancer choose
primary androgen deprivation therapy (PADT) as the
primary therapy. We have previously reported that there
is a significant difference in the risk classification and
primary therapy between Japanese and USA patients [1].
The proportion of high risk patients was significantly
higher in Japan than in the USA, and the proportion of
patients undergoing PADT was also significantly higher in* Correspondence: sendo@naramed-u.ac.jp
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reproduction in any medium, provided the orJapan than the USA [2-4]. Following our first report, we
have conducted a further investigation between 2007
and 2009.
In this paper, we report the trend of risk classification
and primary therapy in patients who were diagnosed
with prostate cancer between 2007 and 2009 in the Nara
Uro-Oncological Research Group (NUORG) registry, and
compare the results with those of the previous survey
performed between 2004 and 2006.Methods
A total of 4752 patients who were newly diagnosed with
prostate cancer at Nara Medical University hospital andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic characteristics of 4752 patients
Overall 2004-06 2007-09 P value
n = 4752 (%) n = 2303 (%) n = 2449 (%)
Age (year)
Younger than 60 278 (5.9) 154 (6.7) 124 (5.1)
60-69 1423 (29.9) 68.4 (29.7) 739 (30.2)
70-79 2367 (49.8) 1117 (48.5) 1250 (51.0)
80 or older 684 (14.4) 348 (15.1) 336 (13.7) 0.036
PSA at diagnosis
10.0 or less 2123 (44.7) 963 (41.8) 1160 (47.4)
10.1-20 1117 (23.5) 554 (24.1) 563 (23.0) <0.001
Greater than 20 1512 (31.8) 786 (34.1) 726 (29.6)
Gleason score
2-6 1771 (37.3) 906 (39.3) 865 (35.3)
7 1614 (34.0) 722 (31.4) 892 (36.4)
8-10 1367 (28.8) 675 (29.3) 692 (28.3) 0.001
Clinical T stage
T1 1605 (33.8) 766 (33.3) 839 (34.3)
T2 1919 (40.4) 933 (40.5) 986 (40.3)
T3 978 (20.6) 489 (21.2) 489 (20.0)
T4 250 (5.3) 115 (5.0) 135 (5.5) 0.593
Clinical N stage
N0 4439 (93.4) 2161 (93.8) 2278 (93.0)
N1 313 (6.6) 142 (6.2) 171 (7.0) 0.141
Clinical M stage
M0 4226 (88.9) 2019 (87.7) 2207 (90.1)
M1a 17 (0.4) 11 (0.5) 6 (0.2)
M1b 468 (9.8) 257 (11.2) 211 (8.6)
M1c 41 (0.9) 16 (0.7) 25 (1.0) 0.008
Risk classification
Low 988 (20.8) 474 (20.6) 514 (21.0)
Intermediate 1252 (26.3) 561 (24.4) 691 (28.2)
High 1232 (25.9) 626 (27.2) 606 (24.7)
Very high 657 (13.8) 319 (13.9) 338 (13.8)
Metastatic 623 (13.1) 323 (14.0) 300 (12.3) <0.001
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December 2009 were enrolled in this retrospective study.
The clinical TNM classification (UICC 2002), biopsy
Gleason score, PSA at diagnosis and primary therapy
were surveyed. We used the risk classification reported
by D’Amico [5]. Patients with cT3-4N0N0 were further
defined as “very high” risk, and patients with node metas-
tasis or distant metastasis were defined as “metastatic.”
We compared the baseline characteristics (stage, PSA
distribution, age, Gleason score, and risk classification)
between the prior (2004-2006) and latter (2007-2009)
periods. Any differences in the primary therapy between
the prior and latter periods were also compared.
To examine the differences in categorical parameters,
the chi-square test was performed. The Mann–Whitney U
test was used to compare metric variables. All statistical
analyses were performed using PASW Statistics 17.0
(SPSS Inc., Chicago, IL, USA). All p values < 0.05 were
considered to be statistically significant.
The Medical Ethics Committee of Nara Medical Univer-
sity approved this retrospective study, and it was exempted
to obtain informed consent from the patients in consider-
ation of the aim and methods of this study.
Results
The demographic characteristics of all 4752 patients are
shown in Table 1. The mean (median) values of patients’
age were 71.8 (72.0) and 71.9 (72.0) years in the prior and
latter periods, respectively. The mean (median) values of
the PSA value at the time of diagnosis in the prior and
latter periods were 137.9 (12.2) and 102.1 (10.8) ng/mL,
respectively. There was a significant difference in the PSA
value at diagnosis between the prior and the latter periods
(p = 0.025, Mann–Whitney U test). The proportions of
older patients and those with a higher PSA value at the
time of diagnosis were significantly higher in the prior
than the latter period (p = 0.036 and p < 0.001). On the
other hand, the proportion of Gleason 7 was significantly
higher in the prior than the latter period (p < 0.001).
There were no differences in the clinical T and N stage
distribution between the two groups, while the proportion
of metastatic patients was significantly higher in the prior
than the latter period (p = 0.008). Regarding risk classifica-
tion, the proportion of high risk patients was significantly
higher in the prior than the latter period (p < 0.001).
Differences in primary therapy
Half of the patients received PADT in the prior period,
while approximately 40% of patients received PADT in
the latter period. Combined androgen blockade (CAB)
was the method used in 90% of these in the prior and
94% of these in the latter period, respectively. The trend to
use CAB was significantly higher in the latter than the prior
period (p < 0.001). The proportion of radical prostatectomy(RP) was the same in the two groups. The proportion
of radiation therapy (RT), including both external beam
radiation therapy (EBRT) and brachytherapy (BT), in-
creased in the latter period. The primary therapy was
thus significantly different between the prior and the
latter periods (p < 0.001) (Figure 1).
The primary therapy had thus changed between the
prior and the latter periods (Figures 2, 3, 4, 5). The use
of PADT decreased significantly. On the other hand, the
proportion of RT increased. Such a significant change
in primary therapy was seen in the low, intermediate




























2004 - 2006 
(n=2303)
2007 - 2009 
(n=2449)
Figure 1 Distribution of the primary therapy of all 4752 patients (Chi-square test; p < 0.001). RP: radical prostatectomy, PADT: primary
androgen deprivation therapy, EBRT: external beam radiation therapy, BT: brachytherapy, AS: active surveillance.
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marginal (p = 0.068).
Discussion
We have previously investigated the trend of risk classifica-
tion and primary therapy in patients who had been diag-
nosed with prostate cancer in the Nara Uro-oncological
Research Group registry between 2004 and 2006 [1]. Half
of the patients showed high risk features and received
PADT according to this report. This result was compatible
with reports by the Japanese Urological Association (JUA)
[3,6] that 57% and 50% of patients received PADT in 2000



















2004 - 2006 
(n=474)
Figure 2 Distribution of the primary therapy of the low risk patients
androgen deprivation therapy, EBRT: external beam radiation therapy, BT: bof PADT and the higher proportion of high risk patients
were distinctive trends among Japanese prostate cancer
patients compared with those in the USA [2,7,8].
Three years after our first report, we conducted the
present study to clarify any changes in the trends of risk
classification and primary therapy in the NUORG data
registry between 2007 and 2009. We found significant
changes both in risk classification and primary therapy.
The proportion of patients with a high or greater risk had
significantly decreased. On the other hand, the proportion
with a low risk remained constant, and that with an inter-
mediate risk increased. The conceivable reason for this











2007 - 2009 
(n=514)
(Chi-square test; p < 0.001). RP: radical prostatectomy, PADT: primary



























2004 - 2006 
(n=561)
2007 - 2009 
(n=691)
Figure 3 Distribution of the primary therapy of the intermediate risk patients (Chi-square test; p = 0.013). RP: radical prostatectomy,
PADT: primary androgen deprivation therapy, EBRT: external beam radiation therapy, BT: brachytherapy, AS: active surveillance.
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and the introduction of the new Gleason grading proposed
by the 2005 International Society of Urologic Pathology
(ISUP) Gleason Grading Consensus [9]. Indeed, the
proportion of patients with a higher PSA value at the
time of diagnosis had significantly decreased, while
the proportion of patients with a Gleason score of 7 had
significantly increased (Table 1) in the present study.
The present study did not only reveal a significant shift
in the risk classification between the prior and latter
periods, but also a higher proportion of patients with a
high or greater risk in Japan than in the USA [10,11].



















2004 - 2006 
(n=626)
Figure 4 Distribution of the primary therapy of the high risk patients
primary androgen deprivation therapy, EBRT: external beam radiation theraPSA exposure rate between the USA and Japan. The PSA
exposure rate was lower in Japan than in the United States
[12,13]. In other words, Japanese urologists still have to
treat patients with a high or greater risk.
Another aspect of the present study was the change in
primary therapy in Japan. Our previous paper showed
that half of the patients received PADT between 2004
and 2006, and doctors at hospitals where modalities
for radiation therapy were not available usually chose
PADT if the patients were unwilling to undergo radical
prostatectomy [1,14]. On the other hand, the proportion
of PADT significantly decreased from 50% to 40% in the
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(Chi-square test; p < 0.001). RP: radical prostatectomy, PADT:
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Figure 5 Distribution of the primary therapy of the very high risk patients (Chi-square test; p = 0.068). RP: radical prostatectomy, PADT:
primary androgen deprivation therapy, EBRT: external beam radiation therapy, BT: brachytherapy, AS: active surveillance.
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therapy had significantly increased from 14% to 24%.
In Japan, low-dose-rate brachytherapy was approved in
2003. Coincidently, intensity modulated radiation therapy
(IMRT) has come to be widely used. The excellent onco-
logic outcome of radiation therapy has been recognized
during the last decade [15,16]. These circumstances likely
had an influence on the decision concerning primary
therapy.
The changes in primary therapy in the low, intermediate,
and high risk groups were also significantly different in
the prior and latter periods (Figures 2, 3, 4). The use of
PADT had significantly decreased and the proportion of
radiation therapy had increased, except for cases with a
very high risk. However, the proportion of PADT in Japan
is still higher than in the USA.Conclusion
A significant shift in risk classification toward a lower risk
could be seen in Japanese prostate cancer patients between
the 2004-2006 and 2007-2009 periods. However, there
were still higher risk patients than in the USA. The primary
therapy also changed during the 3 years. The use of PADT
strongly decreased and the proportion of radiation therapy
increased, not only in the overall population, but also in
each risk group separately.
Abbreviations
PADT: Primary androgen deprivation therapy; NUORG: Nara Uro-Oncological
Research Group; PSA: Prostate-specific antigen,; RP: Radical prostatectomy;
RT: Radiation therapy; EBRT: External beam radiation therapy;
BT: Brachytherapy.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
All authors made substantial contributions to the acquisition and
interpretation of data, critical revision of the manuscript for important
intellectual content, and approved the final version for publication. KF made
substantial contributions to the conception and design of the study.
NT performed the statistical analysis.
Author details
1Department of Urology, Nara Medical University, Nara, Japan. 2Department
of Pathology, Nara Medical University, Nara, Japan.
Received: 4 April 2013 Accepted: 4 December 2013
Published: 10 December 2013References
1. Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y: Trends of the
primary therapy for patients with prostate cancer in Nara uro-oncological
research group (NUORG): a comparison between the CaPSURE data and
the NUORG data. Jpn J Clin Oncol 2010, 40:588–592.
2. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR: CaPSURE: time trends in
clinical risk stratification for prostate cancer: implications for outcomes
(data from CaPSURE). J Urol 2003, 170:S21–S27.
3. Cancer Registration Committee of the Japanese Urological Association:
Clinicopathological statistics on registered prostate cancer patients in
Japan: 2000 report from the Japanese Urological Association. Int J Urol
2005, 12:46–61.
4. Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T,
Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H: Japan study group of
prostate cancer (J-CaP): current status of endocrine therapy for prostate
cancer in Japan analysis of primary androgen deprivation therapy on
the basis of data collected by J-CaP. Jpn J Clin Oncol 2007, 37:775–781.
5. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA,
Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical
outcome after radical prostatectomy, external beam radiation therapy,
or interstitial radiation therapy for clinically localized prostate cancer.
JAMA 1998, 280:969–974.
6. Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO,
Mikami K, Homma Y: Oncological outcomes of the prostate cancer
patients registered in 2004: report from the cancer registration
committee of the JUA. Int J Urol 2011, 18:876–881.
7. Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ:
Sociodemographic and clinical risk characteristics of patients with
prostate cancer within the veterans affairs health care system: data from
CaPSURE. J Urol 2003, 170:905–908.
Tanaka et al. BMC Cancer 2013, 13:588 Page 6 of 6
http://www.biomedcentral.com/1471-2407/13/5888. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends
in low risk prostate cancer: risk assessment and treatment. J Urol 2007,
178:S14–S19.
9. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Grading ISUP: Committee:
the international society of urological pathology (ISUP) consensus
conference on gleason grading of prostatic carcinoma. Am J Surg Pathol
2005, 2005(29):1228–1242.
10. Cooperberg MR, Cowan J, Broering JM, Carroll PR: High-risk prostate
cancer in the United States, 1990-2007. World J Urol 2008, 26:211–218.
11. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H:
Risk assessment among prostate cancer patients receiving primary
androgen deprivation therapy. J Clin Oncol 2009, 27:4306–4313.
12. Ito K, Kakehi Y, Naito S, Okuyama A, Japanese Urological Association: Japanese
urological association guidelines on prostate-specific antigen-based
screening for prostate cancer and the ongoing cluster cohort study in
Japan. Int J Urol 2008, 15:763–768.
13. Sirovich BE, Schwartz LM, Woloshin S: Screening men for prostate and
colorectal cancer in the United States: does practice reflect the
evidence? JAMA 2003, 289:1414–1420.
14. Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y,
Haramoto M, Hayashi Y, Nakagawa Y, Otani T, Watanabe S, Hirao Y: The
primary therapy chosen for patients with localized prostate cancer
between the university hospital and its affiliated hospitals in Nara
uro-oncological research group registration. BMC Urol 2011, 11:6.
15. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A:
Long-term failure patterns and survival in a randomized dose-escalation
trial for prostate cancer: who dies of disease? Int J Radiat Oncol Biol Phys
2011, 79:1310–1317.
16. Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG: Influence of
pretreatment and treatment factors on intermediate to long-term
outcome after prostate brachytherapy. J Urol 2011, 185:495–500.
doi:10.1186/1471-2407-13-588
Cite this article as: Tanaka et al.: Trends of risk classification and primary
therapy for Japanese patients with prostate cancer in Nara Uro-
Oncological Research Group (NUORG)–a comparison between 2004-
2006 and 2007-2009. BMC Cancer 2013 13:588.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
